Does TENOFOVIR ALAFENAMIDE Cause Neoplasm malignant? 52 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Neoplasm malignant have been filed in association with TENOFOVIR ALAFENAMIDE (VEMLIDY). This represents 1.7% of all adverse event reports for TENOFOVIR ALAFENAMIDE.
52
Reports of Neoplasm malignant with TENOFOVIR ALAFENAMIDE
1.7%
of all TENOFOVIR ALAFENAMIDE reports
9
Deaths
11
Hospitalizations
How Dangerous Is Neoplasm malignant From TENOFOVIR ALAFENAMIDE?
Of the 52 reports, 9 (17.3%) resulted in death, 11 (21.2%) required hospitalization.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TENOFOVIR ALAFENAMIDE. However, 52 reports have been filed with the FAERS database.
What Other Side Effects Does TENOFOVIR ALAFENAMIDE Cause?
Death (217)
Product dose omission issue (153)
Off label use (96)
Drug ineffective (93)
Fatigue (92)
Headache (71)
Product dose omission (69)
Intentional dose omission (67)
Product use issue (67)
Nausea (64)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which TENOFOVIR ALAFENAMIDE Alternatives Have Lower Neoplasm malignant Risk?
TENOFOVIR ALAFENAMIDE vs TENOFOVIR DISOPROXIL
TENOFOVIR ALAFENAMIDE vs TEPLIZUMAB-MZWV
TENOFOVIR ALAFENAMIDE vs TEPOTINIB
TENOFOVIR ALAFENAMIDE vs TEPROTUMUMAB
TENOFOVIR ALAFENAMIDE vs TEPROTUMUMAB-TRBW